We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




First-of-its-Kind Blood Test Detects Trauma-Related Diseases

By LabMedica International staff writers
Posted on 24 Apr 2025

In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. More...

Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret these stress signals as threats, similar to an infection. This misinterpretation triggers an autoimmune response, where the immune system mistakenly attacks the body, resulting in a cycle of inflammation. The longer this cycle persists, the greater the damage to both mental and physical health. Studies have shown that chronic inflammation leads to oxidative stress in the brain, a condition that contributes to mental health challenges such as anxiety, depression, and other disorders. This inflammation doesn’t just affect mental health; it also leads to a range of physical conditions, including autoimmune disorders, cardiovascular diseases, and chronic pain. Essentially, unresolved trauma and prolonged stress disrupt the body’s response systems, ultimately affecting behavior, personality, and overall well-being. Now, a simple blood test can identify biological markers of trauma-induced conditions before the onset of disease.

iXpressGenes (Huntsville, AL, USA) has discovered that prolonged stress and trauma can lead to differentiated inflammation and autoimmune responses in the body. These immune responses can result in serious trauma-induced diseases, including post-traumatic stress disorder (PTSD), autoimmune conditions, chronic pain syndromes, cardiovascular diseases, and more. These conditions can be detected through specific RNA biomarkers. iXpressGenes has developed a diagnostic aid using a biomarker technology that revolutionizes early detection and prevention of PTSD, anxiety, and depression, thereby modernizing mental health care. Identifying these biomarkers may aid in preventing and treating trauma-induced diseases, such as PTSD, autoimmune disorders, and chronic pain syndromes. The company’s Trauma Autoimmune Indicator (TAI) test is a proprietary, blood-based RNA biomarker technology that helps healthcare professionals detect biological changes caused by trauma, enabling proactive prevention of trauma-related diseases.

TAI screening represents a breakthrough in trauma care by detecting trauma-induced inflammation at the cellular level before symptoms appear. By analyzing RNA and identifying specific protein dysregulations associated with immune response, TAI screening reveals the hidden changes trauma causes in the body. This early detection not only helps identify the impact of trauma but also provides valuable insights for timely intervention, reducing the risk of long-term health complications. Just like how a cholesterol test aids in preventing heart attacks and other cardiovascular conditions through early intervention, early detection of trauma-related biomarkers can help providers shift from reactive treatment to proactive prevention of trauma-induced diseases.

Related Links:
iXpressGenes


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.